SKTO SK3 Group Inc (CE)

SK3 Group Announces Sales of New Product T-Hydrocan(TM) CBD 10/5

LOS ANGELES, CA--(Marketwired - Jun 16, 2014) - SK3 Group, Inc. (OTC Pink: SKTO) (PINKSHEETS: SKTO) ("the Company") is pleased to announce that the first bottles of its new medicinal cannabis product, T-Hydrocan™ CBD 10/5, is now available from Pharmajanes.com, and will soon be available from collectives that carry the Company's YAK Edibles line of medical marijuana products. T-Hydrocan™ CBD 10/5 is the third offering in Berkeley Bio's cannabinoid-based nutraceutical product line, joining Dharmamol™ and T-Hydrocan™ RMC 40.

The "CBD 10/5" indicates that each dosage unit contains 10mg. of CBD and 5 mg. of THC. The THC is in its fully activated (decarboxylated) form. The cannabis oils have been thoroughly refined utilizing organic processing materials which have been approved for contact with food, yielding a translucent red or gold colored essential oil containing highly concentrated cannabinoids.

T-Hydrocan™ CBD 10/5 is packaged 8 tablets per bottle. The suggested retail price is $30.00 per bottle.

T-Hydrocan™ CBD 10/5 was developed by Berkeley Bio-Organic Research Laboratories, Inc. and is available through Pharmajanes.com and select dispensaries throughout California.

"We are thrilled that we have been able to get this product to market this quickly," said David Hoye, head of Berkeley Bio-Organic Research Laboratories and director of the Company. "This product will undoubtedly help many patients improve their quality of life while realizing the benefits of CBD."

FDA Statement The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.

About SK3 SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.

Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: SK3 Group, Inc. investors@medicalgreens.com Investor Relations